Discovery Pharma Conzerol zero molluscum contagiosum Recall

Why it was recalled

CGMP deviations

Product description

Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Topical Cream, Net weight 0.78 oz (22g) tube, UPC 8 60322 00180 8, Manufactured by: Dr. Retter EC Warszawska 17, 05-075 Warszawa Poland

Lot numbers, UPCs & expiration codes

Lots: 22123 Exp. 01/2024; 21732 Exp. 07/2023

Where it was sold

CA, FL, WA

What to do if you have this product

Compare the lot number and expiration date on your package with the codes above.
Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
If you have symptoms you think are related, contact your doctor. In an emergency call 911.
Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number: D-0261-2023
Classification: Class II
Status: Terminated
Recall initiated: Nov 9, 2022
FDA report date: Feb 8, 2023
Quantity: 21,892 tubes
Recall type: Voluntary: Firm initiated
Recalling firm: DISCOVERY PHARMA LLC

Original FDA data

Every field from FDA enforcement report D-0261-2023, exactly as published.

Show all FDA fields

City: Oviedo
State: FL
Status: Terminated
Country: United States
Event ID: 91559
Address: 815 Eyrie Dr Ste 3
Code information: Lots: 22123 Exp. 01/2024; 21732 Exp. 07/2023
Postal code: 32765-8602
Report date: Feb 8, 2023
Product type: Drugs
Recall number: D-0261-2023
Classification: Class II
Recalling firm: DISCOVERY PHARMA LLC
Product quantity: 21,892 tubes
Termination date: Apr 29, 2024
Reason for recall: CGMP deviations
Voluntary / mandated: Voluntary: Firm initiated
Product description: Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Topical Cream, Net weight 0.78 oz (22g) tube, UPC 8 60322 00180 8, Manufactured by: Dr. Retter EC Warszawska 17, 05-075 Warszawa Poland
Distribution pattern: CA, FL, WA
Recall initiation date: Nov 9, 2022
Initial firm notification: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date: Feb 1, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0261-2023, published Feb 8, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: Oct 2, 2026. Content last changed: Oct 2, 2026.

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.